Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005779
Status:
COMPLETED
Last Update Posted:
2021-11-01
First Post:
2000-06-03
Brief Title:
Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 IL-12 in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy
Sponsor:
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
12
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: